Max Access Solutions is our innovative, patient-centered model for delivering cancer treatment to those in need. Through the program, launched in 2017, we connect people facing cancer in countries where treatment is not locally available to high-impact medicines, qualified medical professionals, and essential support services.
This work is made possible through partnerships with local physicians, ministries of health, other non-governmental organizations, patient organizations, and medicine manufacturers. Our partner physicians play a vital role in receiving the medication at the local level, enrolling patients into the program, and providing the individual care each patient needs.
Max Access Solutions is meant to bridge access to treatment in underserved areas, with a focus on low- and middle-income countries, until local access channels can be put in place.
- 35K+
patients provided access to medication and/or support services each year
- 80+
countries where medication access and/or support services are provided
- 15
medicines provided
Our Cancer Programs
For over 25 years, we’ve developed our cancer programs and expanded our partnerships to reach cancer patients in more than 80 low- and middle-income countries. We now offer a wide portfolio of life-extending medications for multiple disease areas and growing.
“The access to drugs, at no cost, has not only helped me financially but also enhanced my overall well-being. This has enabled me to sustain my occupation as a farmer, which demands immense endurance and physical strength. As a patient facing financial constraints, the provision of such vital medication is invaluable, and I cannot express enough gratitude to The Max Foundation, [the pharmaceutical company], and my treating physicians for facilitating access to this treatment.”
– Serali, a farmer, father, and grandfather from Nepal living with chronic myeloid leukemia
Latest Developments
The Max Foundation (Max) and its Partners Unveil Breakthrough Cancer Care Commitment to Double Their Impact and Reach 100,000 Patients Annually by 2030
Building on two decades of progress, Max’s ambitious goal will expand its proven, patient-centered model that has already helped more than 100,000 people access treatment Commitment will enhance local health system capabilities to deliver innovative and generic medicines, diagnostics, and treatment in more than 80 low- and middle-income countries Alongside this commitment, Max and Novartis sign….
Interviews with VJHemOnc
At the 13th Annual SOHO Meeting in Houston (Sept 3–6, 2025), Andrielle Yost, Associate Director of Public Sector Engagement at The Max Foundation, discusses the work the organization is doing to improve access to chronic lymphocytic leukemia (CLL) treatment for patients in low- and middle-income countries (LMICs). Watch the interview here. You can also watch….
Overcoming Barriers to Access
Improving health outcomes for people living with cancer is about more than medication. We provide access to psychosocial support, transportation assistance, adherence monitoring, and more to ensure patient needs are handled individually and holistically.
Learn More
2024 M&E Report
Download Report